Emilie Duchesneau

Suggest Changes
Learn More
BACKGROUND When considering optimal second-line treatments for metastatic renal cell carcinoma (mRCC), clinicians and payers seek to understand the relative clinical benefits and costs of treatment.(More)
  • 1